Article

Fred R. Hirsch Discusses His Own Cancer Diagnosis

Author(s):

Fred R. Hirsch, MD

Fred R. Hirsch, from the University of Colorado and IASLC, discusses some of the unique challenges he faced as a patient.

Fred R. Hirsch, professor of medicine, professor in pathology, University of Colorado, CEO, International Associate for the Study of Lung Cancer (IASLC), discusses some of the unique challenges he faced as a patient.

When Hirsch was diagnosed with lymphoma, he had been practicing medical oncology for 20 years. Before that moment, Hirsch admits, he thought he knew everything about cancer and cancer treatment. Then, new perspectives came flooding in.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
image of gerds
Image of 2 doctors and text.
Image of two doctors and text.
Image of man.
Image of thumbnail.
Patients can prepare personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner in an interview with CURE.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Expanding on a New Way to Manage Polycythemia Vera Without Iron Deficiency
Image of woman.
Image of two people.
Related Content
Image of hands.
June 14th 2025

From Patient to Researcher: It’s Not All About the Cure

Jessica López
I’m working to make cancer treatments less painful by developing donor-derived CAR therapies, so others don’t have to suffer the way I did.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
The first patient has been dosed in the phase 3 TERZO trial of Copiktra for R/R nodal T-follicular helper cell lymphoma: © stock.adobe.com.
June 9th 2025

TERZO Trial Doses First Patient With Copiktra in Rare T-Cell Lymphoma

Spencer Feldman
The first patient has been dosed in the phase 3 TERZO trial of Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Columvi combo enhances survival outcomes vs Rituxan combo in R/R DLBCL: © stock.adobe.com.
June 5th 2025

Columvi Combo Enhances Survival Outcomes in R/R Lymphoma Subgroup

Roman Fabbricatore
Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma.
Linda Cohen is a survivor of small lymphocytic lymphoma and was diagnosed in 2009. Catch up on all of Linda's blogs here!
June 3rd 2025

You Are Not a Statistic: Facing Cancer With Hope, Not Numbers

Linda Cohen
I’m here to prove that powerful phrase; after nearly 16 years living with incurable cancer, I know there’s more to my story than the statistics.